Antibodies in cancer immunotherapy

Lavakumar Karyampudi, Keith L Knutson

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Monoclonal antibodies are currently being used as potential therapeutics against cancer. So far, eight monoclonal antibodies have been approved by FDA for human use and all these antibodies are effective in the treatment of patients with variety of cancers. Also, there is a long list of several antibodies which are in late stage clinical trials awaiting potential approval by the FDA for use in the clinic. Monoclonal antibodies exert their effects on tumor cells either directly or indirectly thereby eliminating or reducing the tumor burden in cancer patients. In this review we will focus our discussion on different monoclonal antibodies that are currently being used for immunotherapy of different types of cancers, their mechanism of action, several strategies that are being used to improve the effectiveness of these monoclonal antibodies and their potential use in combination therapy approaches along with different chemotherapeutic agents. The field of antibody therapy has ushered in a new and vast research paradigm that is definitely impacting public health.

Original languageEnglish (US)
Pages (from-to)291-305
Number of pages15
JournalCancer Biomarkers
Volume6
Issue number5-6
DOIs
StatePublished - 2009

Fingerprint

Immunotherapy
Monoclonal Antibodies
Antibodies
Neoplasms
Therapeutics
Tumor Burden
Public Health
Clinical Trials
Research

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Genetics

Cite this

Antibodies in cancer immunotherapy. / Karyampudi, Lavakumar; Knutson, Keith L.

In: Cancer Biomarkers, Vol. 6, No. 5-6, 2009, p. 291-305.

Research output: Contribution to journalArticle

Karyampudi, Lavakumar ; Knutson, Keith L. / Antibodies in cancer immunotherapy. In: Cancer Biomarkers. 2009 ; Vol. 6, No. 5-6. pp. 291-305.
@article{965213a6a1e94c118f51a51ab7de254d,
title = "Antibodies in cancer immunotherapy",
abstract = "Monoclonal antibodies are currently being used as potential therapeutics against cancer. So far, eight monoclonal antibodies have been approved by FDA for human use and all these antibodies are effective in the treatment of patients with variety of cancers. Also, there is a long list of several antibodies which are in late stage clinical trials awaiting potential approval by the FDA for use in the clinic. Monoclonal antibodies exert their effects on tumor cells either directly or indirectly thereby eliminating or reducing the tumor burden in cancer patients. In this review we will focus our discussion on different monoclonal antibodies that are currently being used for immunotherapy of different types of cancers, their mechanism of action, several strategies that are being used to improve the effectiveness of these monoclonal antibodies and their potential use in combination therapy approaches along with different chemotherapeutic agents. The field of antibody therapy has ushered in a new and vast research paradigm that is definitely impacting public health.",
author = "Lavakumar Karyampudi and Knutson, {Keith L}",
year = "2009",
doi = "10.3233/CBM-2009-0141",
language = "English (US)",
volume = "6",
pages = "291--305",
journal = "Cancer Biomarkers",
issn = "1574-0153",
publisher = "IOS Press",
number = "5-6",

}

TY - JOUR

T1 - Antibodies in cancer immunotherapy

AU - Karyampudi, Lavakumar

AU - Knutson, Keith L

PY - 2009

Y1 - 2009

N2 - Monoclonal antibodies are currently being used as potential therapeutics against cancer. So far, eight monoclonal antibodies have been approved by FDA for human use and all these antibodies are effective in the treatment of patients with variety of cancers. Also, there is a long list of several antibodies which are in late stage clinical trials awaiting potential approval by the FDA for use in the clinic. Monoclonal antibodies exert their effects on tumor cells either directly or indirectly thereby eliminating or reducing the tumor burden in cancer patients. In this review we will focus our discussion on different monoclonal antibodies that are currently being used for immunotherapy of different types of cancers, their mechanism of action, several strategies that are being used to improve the effectiveness of these monoclonal antibodies and their potential use in combination therapy approaches along with different chemotherapeutic agents. The field of antibody therapy has ushered in a new and vast research paradigm that is definitely impacting public health.

AB - Monoclonal antibodies are currently being used as potential therapeutics against cancer. So far, eight monoclonal antibodies have been approved by FDA for human use and all these antibodies are effective in the treatment of patients with variety of cancers. Also, there is a long list of several antibodies which are in late stage clinical trials awaiting potential approval by the FDA for use in the clinic. Monoclonal antibodies exert their effects on tumor cells either directly or indirectly thereby eliminating or reducing the tumor burden in cancer patients. In this review we will focus our discussion on different monoclonal antibodies that are currently being used for immunotherapy of different types of cancers, their mechanism of action, several strategies that are being used to improve the effectiveness of these monoclonal antibodies and their potential use in combination therapy approaches along with different chemotherapeutic agents. The field of antibody therapy has ushered in a new and vast research paradigm that is definitely impacting public health.

UR - http://www.scopus.com/inward/record.url?scp=77958167073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958167073&partnerID=8YFLogxK

U2 - 10.3233/CBM-2009-0141

DO - 10.3233/CBM-2009-0141

M3 - Article

C2 - 20938089

AN - SCOPUS:77958167073

VL - 6

SP - 291

EP - 305

JO - Cancer Biomarkers

JF - Cancer Biomarkers

SN - 1574-0153

IS - 5-6

ER -